Late antibody-mediated rejection in renal allografts: Outcome after conventional and novel therapies

Transplantation

Volumn 97, Issue 12, 2014, Pages 1240-1246

  Gupta, Gaurav ^a   Abu Jawdeh, Bassam G ^b   Racusen, Lorraine C ^c   Bhasin, Bhavna ^c   Arend, Lois J ^c   Trollinger, Brandon ^d   Kraus, Edward ^c   Rabb, Hamid ^c   Zachary, Andrea A ^c   Montgomery, Robert A ^c   Alachkar, Nada ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Bortezomib; Kidney; Late AMR; Rituximab; Transplant

Indexed keywords

BORTEZOMIB; CREATININE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS;

ADULT; AGE DISTRIBUTION; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; LATE ANTIBODY MEDIATED REJECTION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; ONSET AGE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PLASMAPHERESIS; PRIORITY JOURNAL; VASCULAR DISEASE;

ADULT; ALLOGRAFTS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BALTIMORE; BIOLOGICAL MARKERS; BORONIC ACIDS; CREATININE; DRUG SUBSTITUTION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLASMAPHERESIS; PYRAZINES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902475012     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000442503.85766.91     Document Type: Article

References (29)

1. Montgomery RA, Hardy MA, Jordan SC, et al. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004; 78: 181.
2. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
3. HaasM, Montgomery RA, Segev DL, et al. Subclinical acute antibodymediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576.
4. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013; 381: 313.
5. Lucas JG, Co JP, Nwaogwugwu UT, et al. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother 2011; 12: 579.
6. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277.
7. Montgomery RA, Cozzi E, West LJ, et al. Humoral immunity and antibody-mediated rejection in solid organ transplantation. Semin Immunol 2011; 23: 224.
8. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124.
9. Péfaur J, D?́az P, Panace R, et al. Early and late humoral rejection: a clinicopathologic entity in two times. Transplant Proc 2008; 40: 3229.
10. Sun Q, Liu Z-H, Ji S, et al. Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation. Kidney Int 2006; 70: 377.
11. Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibodymediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011; 91: 1218.
12. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099.
13. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
14. Waiser J, Budde K, Schütz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant 2012; 27: 1246.
15. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168.
16. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
17. Walsh RC, Alloway RR, Girnita AL, et al. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int 2012; 81: 1067.
18. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
19. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388.
20. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438.
21. Amer H, Fidler ME, Myslak M, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007; 7: 2748.
22. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
23. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO-and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006; 6: 1829.
24. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
25. Constantiner M, Sehgal AR, Humbert L, et al. A dipstick protein and specific gravity algorithm accurately predicts pathological proteinuria. Am J Kidney Dis 2005; 45: 833.
26. Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87: 1246.
27. Hetrick SJ, Schillinger KP, Zachary AA, Jackson AM. Impact of pronase on flow cytometric crossmatch outcome. Hum Immunol 2011; 72: 330.
28. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLAincompatible kidney recipients and survival. N Engl J Med 2011; 365: 318.
29. Zachary AA, Sholander JT, Houp JA, et al. Using real data for a virtual crossmatch. Hum Immunol 2009; 70: 574.